Pomalidomide in the management of relapsed multiple myeloma
Pomalidomide, a very potent member of the immunomodulatory drug family, is considered a standard of care for patients with relapsed and refractory myeloma, who have previously been treated with bortezomib and lenalidomide. Pomalidomide induces both direct myeloma cell death, and indirect antimyeloma...
Gespeichert in:
| Veröffentlicht in: | Future oncology (London, England) England), 2016-09, Vol.12 (17), p.1975-1983 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1983 |
|---|---|
| container_issue | 17 |
| container_start_page | 1975 |
| container_title | Future oncology (London, England) |
| container_volume | 12 |
| creator | Touzeau, Cyrille Moreau, Philippe |
| description | Pomalidomide, a very potent member of the immunomodulatory drug family, is considered a standard of care for patients with relapsed and refractory myeloma, who have previously been treated with bortezomib and lenalidomide. Pomalidomide induces both direct myeloma cell death, and indirect antimyeloma response through its impact on the microenvironment (modulation of immune response, inhibition of angiogenesis, inhibition of bone resorption). Pomalidomide in combination with dexamethasone is an approved regimen in Europe and USA based on the results of a Phase III randomized trial. In order to improve response rate and patient survival, pomalidomide is currently being assessed in triplet combinations with other antimyeloma agents. The present review addresses current knowledge regarding the clinical use of pomalidomide in relapsed myeloma patients. |
| doi_str_mv | 10.2217/fon-2016-0184 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_inserm_01411106v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2275216992</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-ee746a756733ee5de2bd3ae40f1ff1df7dbb630d91b2b64bde63606b789a5b4b3</originalsourceid><addsrcrecordid>eNp10UFvFSEQB3BiNLZWj17NJl48uMoAC7vx1DRqTV6iBz0TWAZLA-wTdk367eVlaw8mnoDwm8nAn5CXQN8xBuq9X3LPKMiewigekXNQQvQjp_C47YWaeikncUae1XpLqVB8oE_JGVNs5GJQ5-TDtyWZGNySgsMu5G69wS6ZbH5iwrx2i-8KRnOs6Lq0xTUcY7u_w9jKnpMn3sSKL-7XC_Lj08fvV9f94evnL1eXh34WdFx7RCWkUYNUnCMODpl13KCgHrwH55WzVnLqJrDMSmEdSi6ptGqczGCF5Rfk7d73xkR9LCGZcqcXE_T15UGHXLEkTUEAAJW_ofE3Oz-W5deGddUp1BljNBmXrWoYgQk-CSkaff0PvV22kttjNGNqYCCniTXV72ouS60F_cMQQPUpBN1C0KcQ9CmE5l_dd91sQveg__56A9MO_LZuBescMM-o91OrCHPI-J_mfwAljZTR</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2275216992</pqid></control><display><type>article</type><title>Pomalidomide in the management of relapsed multiple myeloma</title><source>MEDLINE</source><source>PubMed Central</source><creator>Touzeau, Cyrille ; Moreau, Philippe</creator><creatorcontrib>Touzeau, Cyrille ; Moreau, Philippe</creatorcontrib><description>Pomalidomide, a very potent member of the immunomodulatory drug family, is considered a standard of care for patients with relapsed and refractory myeloma, who have previously been treated with bortezomib and lenalidomide. Pomalidomide induces both direct myeloma cell death, and indirect antimyeloma response through its impact on the microenvironment (modulation of immune response, inhibition of angiogenesis, inhibition of bone resorption). Pomalidomide in combination with dexamethasone is an approved regimen in Europe and USA based on the results of a Phase III randomized trial. In order to improve response rate and patient survival, pomalidomide is currently being assessed in triplet combinations with other antimyeloma agents. The present review addresses current knowledge regarding the clinical use of pomalidomide in relapsed myeloma patients.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2016-0184</identifier><identifier>PMID: 27283457</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Angiogenesis ; Antineoplastic Agents - therapeutic use ; Cancer ; Cell cycle ; Clinical Trials as Topic ; Cytotoxicity ; Drug dosages ; Humans ; Life Sciences ; Medical prognosis ; Multiple myeloma ; Multiple Myeloma - drug therapy ; myeloma ; Neoplasm Recurrence, Local - drug therapy ; Neutropenia ; pomalidomide ; Response rates ; Thalidomide - analogs & derivatives ; Thalidomide - therapeutic use</subject><ispartof>Future oncology (London, England), 2016-09, Vol.12 (17), p.1975-1983</ispartof><rights>Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd Sep 2016</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-ee746a756733ee5de2bd3ae40f1ff1df7dbb630d91b2b64bde63606b789a5b4b3</citedby><cites>FETCH-LOGICAL-c408t-ee746a756733ee5de2bd3ae40f1ff1df7dbb630d91b2b64bde63606b789a5b4b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27283457$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://inserm.hal.science/inserm-01411106$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Touzeau, Cyrille</creatorcontrib><creatorcontrib>Moreau, Philippe</creatorcontrib><title>Pomalidomide in the management of relapsed multiple myeloma</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>Pomalidomide, a very potent member of the immunomodulatory drug family, is considered a standard of care for patients with relapsed and refractory myeloma, who have previously been treated with bortezomib and lenalidomide. Pomalidomide induces both direct myeloma cell death, and indirect antimyeloma response through its impact on the microenvironment (modulation of immune response, inhibition of angiogenesis, inhibition of bone resorption). Pomalidomide in combination with dexamethasone is an approved regimen in Europe and USA based on the results of a Phase III randomized trial. In order to improve response rate and patient survival, pomalidomide is currently being assessed in triplet combinations with other antimyeloma agents. The present review addresses current knowledge regarding the clinical use of pomalidomide in relapsed myeloma patients.</description><subject>Angiogenesis</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer</subject><subject>Cell cycle</subject><subject>Clinical Trials as Topic</subject><subject>Cytotoxicity</subject><subject>Drug dosages</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Medical prognosis</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - drug therapy</subject><subject>myeloma</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neutropenia</subject><subject>pomalidomide</subject><subject>Response rates</subject><subject>Thalidomide - analogs & derivatives</subject><subject>Thalidomide - therapeutic use</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp10UFvFSEQB3BiNLZWj17NJl48uMoAC7vx1DRqTV6iBz0TWAZLA-wTdk367eVlaw8mnoDwm8nAn5CXQN8xBuq9X3LPKMiewigekXNQQvQjp_C47YWaeikncUae1XpLqVB8oE_JGVNs5GJQ5-TDtyWZGNySgsMu5G69wS6ZbH5iwrx2i-8KRnOs6Lq0xTUcY7u_w9jKnpMn3sSKL-7XC_Lj08fvV9f94evnL1eXh34WdFx7RCWkUYNUnCMODpl13KCgHrwH55WzVnLqJrDMSmEdSi6ptGqczGCF5Rfk7d73xkR9LCGZcqcXE_T15UGHXLEkTUEAAJW_ofE3Oz-W5deGddUp1BljNBmXrWoYgQk-CSkaff0PvV22kttjNGNqYCCniTXV72ouS60F_cMQQPUpBN1C0KcQ9CmE5l_dd91sQveg__56A9MO_LZuBescMM-o91OrCHPI-J_mfwAljZTR</recordid><startdate>20160901</startdate><enddate>20160901</enddate><creator>Touzeau, Cyrille</creator><creator>Moreau, Philippe</creator><general>Future Medicine Ltd</general><general>Future Medicine</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope></search><sort><creationdate>20160901</creationdate><title>Pomalidomide in the management of relapsed multiple myeloma</title><author>Touzeau, Cyrille ; Moreau, Philippe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-ee746a756733ee5de2bd3ae40f1ff1df7dbb630d91b2b64bde63606b789a5b4b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Angiogenesis</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer</topic><topic>Cell cycle</topic><topic>Clinical Trials as Topic</topic><topic>Cytotoxicity</topic><topic>Drug dosages</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Medical prognosis</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - drug therapy</topic><topic>myeloma</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neutropenia</topic><topic>pomalidomide</topic><topic>Response rates</topic><topic>Thalidomide - analogs & derivatives</topic><topic>Thalidomide - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Touzeau, Cyrille</creatorcontrib><creatorcontrib>Moreau, Philippe</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Touzeau, Cyrille</au><au>Moreau, Philippe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pomalidomide in the management of relapsed multiple myeloma</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2016-09-01</date><risdate>2016</risdate><volume>12</volume><issue>17</issue><spage>1975</spage><epage>1983</epage><pages>1975-1983</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>Pomalidomide, a very potent member of the immunomodulatory drug family, is considered a standard of care for patients with relapsed and refractory myeloma, who have previously been treated with bortezomib and lenalidomide. Pomalidomide induces both direct myeloma cell death, and indirect antimyeloma response through its impact on the microenvironment (modulation of immune response, inhibition of angiogenesis, inhibition of bone resorption). Pomalidomide in combination with dexamethasone is an approved regimen in Europe and USA based on the results of a Phase III randomized trial. In order to improve response rate and patient survival, pomalidomide is currently being assessed in triplet combinations with other antimyeloma agents. The present review addresses current knowledge regarding the clinical use of pomalidomide in relapsed myeloma patients.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>27283457</pmid><doi>10.2217/fon-2016-0184</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2016-09, Vol.12 (17), p.1975-1983 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_inserm_01411106v1 |
| source | MEDLINE; PubMed Central |
| subjects | Angiogenesis Antineoplastic Agents - therapeutic use Cancer Cell cycle Clinical Trials as Topic Cytotoxicity Drug dosages Humans Life Sciences Medical prognosis Multiple myeloma Multiple Myeloma - drug therapy myeloma Neoplasm Recurrence, Local - drug therapy Neutropenia pomalidomide Response rates Thalidomide - analogs & derivatives Thalidomide - therapeutic use |
| title | Pomalidomide in the management of relapsed multiple myeloma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T21%3A03%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pomalidomide%20in%20the%20management%20of%20relapsed%20multiple%20myeloma&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Touzeau,%20Cyrille&rft.date=2016-09-01&rft.volume=12&rft.issue=17&rft.spage=1975&rft.epage=1983&rft.pages=1975-1983&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2016-0184&rft_dat=%3Cproquest_hal_p%3E2275216992%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2275216992&rft_id=info:pmid/27283457&rfr_iscdi=true |